Piperidine Nucleus as a Promising Scaffold for Alzheimer’s Disease: Current Landscape and Future Perspective

Author:

Grover Parul1,Rohilla Suman2,Bhardwaj Monika3,Mehta Lovekesh4,Malhotra Anjleena1

Affiliation:

1. KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, 201206, India

2. SGT college of pharmacy, Shree Guru Gobind Singh Tricentenary University, Gurugram. Haryana, 122505, India

3. Natural Product and Medicinal Chemistry Division, Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu, 180001, India

4. Amity Institute of Pharmacy, Amity University, Noida, 201301, India

Abstract

Abstract: Heterocycles and their derivatives hold an important place in medicinal chemistry due to their vast therapeutic and pharmacological significance and wider implications in drug design and development. Piperidine is a nitrogen-containing heterocyclic moiety that exhibits an array of pharmacological properties. This review discusses the potential of piperidine derivatives against the neurodegenerative disease Alzheimer’s. The incidences of Alzheimer’s disease are increasing nowadays, and constant efforts are being made to develop a medicinal agent for this disease. We have highlighted the advancement in developing piperidine-based anti-neuronal disease compounds and the profound activities of some major piperidine-bearing drug molecules with their important target site. : This review focuses on advancements in the field of natural and synthetic occurring piperidines active against Alzheimer’s disease, with emphasis on the past 6 years. The discussion also includes the structure-activity relationship, the structures of the most promising molecules, and their biological activities against Alzheimer’s disease. The promising activities revealed by these piperidinebased scaffolds undoubtedly place them at the forefront of discovering prospective drug candidates. Thus, it would be of great interest to researchers working on synthesizing neuroprotective drug candidates.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference106 articles.

1. Hippius H.; Neundörfer G.; The discovery of Alzheimer’s disease. Dialogues Clin Neurosci 2003,5(1),101-108

2. Terracciano A.; Sutin A.R.; Personality and Alzheimer’s disease: An integrative review. Pers Disord 2019,10(1),4-12

3. Niu H.; Alvarez-Alvarez I.; Guillen-Grima F.; Al-Rahamneh M.J.; Aguinaga-Ontoso I.; Trends of mortality from Alzheimer’s disease in the European Union, 1994-2013. Eur J Neurol 2017,24(6),858-866

4. Nichols E.; Szoeke C.E.I.; Vollset S.E.; Abbasi N.; Abd-Allah F.; Abdela J.; Aichour M.T.E.; Akinyemi R.O.; Alahdab F.; Asgedom S.W.; Awasthi A.; Barker-Collo S.L.; Baune B.T.; Béjot Y.; Belachew A.B.; Bennett D.A.; Biadgo B.; Bijani A.; Bin Sayeed M.S.; Brayne C.; Carpenter D.O.; Carvalho F.; Catalá-López F.; Cerin E.; Choi J-Y.J.; Dang A.K.; Degefa M.G.; Djalalinia S.; Dubey M.; Duken E.E.; Edvardsson D.; Endres M.; Eskandarieh S.; Faro A.; Farzadfar F.; Fereshtehnejad S-M.; Fernandes E.; Filip I.; Fischer F.; Gebre A.K.; Geremew D.; Ghasemi-Kasman M.; Gnedovskaya E.V.; Gupta R.; Hachinski V.; Hagos T.B.; Hamidi S.; Hankey G.J.; Haro J.M.; Hay S.I.; Irvani S.S.N.; Jha R.P.; Jonas J.B.; Kalani R.; Karch A.; Kasaeian A.; Khader Y.S.; Khalil I.A.; Khan E.A.; Khanna T.; Khoja T.A.M.; Khubchandani J.; Kisa A.; Kissimova-Skarbek K.; Kivimäki M.; Koyanagi A.; Krohn K.J.; Logroscino G.; Lorkowski S.; Majdan M.; Malekzadeh R.; März W.; Massano J.; Mengistu G.; Meretoja A.; Mohammadi M.; Mohammadi-Khanaposhtani M.; Mokdad A.H.; Mondello S.; Moradi G.; Nagel G.; Naghavi M.; Naik G.; Nguyen L.H.; Nguyen T.H.; Nirayo Y.L.; Nixon M.R.; Ofori-Asenso R.; Ogbo F.A.; Olagunju A.T.; Owolabi M.O.; Panda-Jonas S.; Passos V.M.A.; Pereira D.M.; Pinilla-Monsalve G.D.; Piradov M.A.; Pond C.D.; Poustchi H.; Qorbani M.; Radfar A.; Reiner R.C.; Robinson S.R.; Roshandel G.; Rostami A.; Russ T.C.; Sachdev P.S.; Safari H.; Safiri S.; Sahathevan R.; Salimi Y.; Satpathy M.; Sawhney M.; Saylan M.; Sepanlou S.G.; Shafieesabet A.; Shaikh M.A.; Sahraian M.A.; Shigematsu M.; Shiri R.; Shiue I.; Silva J.P.; Smith M.; Sobhani S.; Stein D.J.; Tabarés-Seisdedos R.; Tovani-Palone M.R.; Tran B.X.; Tran T.T.; Tsegay A.T.; Ullah I.; Venketasubramanian N.; Vlassov V.; Wang Y-P.; Weiss J.; Westerman R.; Wijeratne T.; Wyper G.M.A.; Yano Y.; Yimer E.M.; Yonemoto N.; Yousefifard M.; Zaidi Z.; Zare Z.; Vos T.; Feigin V.L.; Murray C.J.L.; Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019,18(1),88-106

5. Park J.; Mortality from Alzheimer’s disease in Canada: A multiple-cause-of-death analysis, 2004 to 2011. Public Health Rep 2016,27(5),17-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3